Interactions : אינטראקציות

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.
Narcotics, hypnotics or sedatives must be administered with caution when used concomitantly with Intron A.

Interactions between Intron A and other medicinal products have not been fully evaluated. Caution must be exercised when administering Intron A in combination with other potentially myelosuppressive agents.

Interferons may affect the oxidative metabolic process. This must be considered during concomitant therapy with medicinal products metabolised by this route, such as the xanthine derivatives theophylline or aminophylline. During concomitant therapy with xanthine agents, serum theophylline levels must be monitored and dose adjusted if necessary.

Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alfa treated patients, including those treated with Intron A. The aetiology has not been defined. These symptoms have been reported more frequently when shosaikoto, a Chinese herbal medicine, is administered concomitantly with interferon alfa (see section 4.4).

Administration of Intron A in combination with other chemotherapeutic agents (e.g., Ara- C, cyclophosphamide, doxorubicin, teniposide) may lead to increased risk of toxicity (severity and duration) (see section 4.4).
Also see ribavirin SPC if Intron A is to be administered in combination with ribavirin in patients with chronic hepatitis C.

A clinical trial investigating the combination of telbivudine, 600 mg daily, with pegylated interferon alfa-2a, 180 micrograms once weekly by subcutaneous administration, indicates that this combination is associated with an increased risk of developing peripheral neuropathy. The mechanism behind these events is not known (see telbivudine SPC). Moreover, the safety and efficacy of telbivudine in combination with interferons for the treatment of chronic hepatitis B has not been demonstrated.
Therefore, the combination of Intron A with telbivudine is contraindicated (see section 4.3).